small molecule

ASTEPRO ALLERGY

AZELASTINE HYDROCHLORIDE

Loss of exclusivityJune 2028latest FDA-listed patent expiry
CompanyBayer Healthcare Consumer Care →See this company's full patent-cliff portfolio

Drug detail

Brand nameASTEPRO ALLERGY
Active ingredientAZELASTINE HYDROCHLORIDE
Strength0.2055MG/SPRAY
Dosage formSPRAY, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalJune 2021
Marketing statusOTC

Listed patents

PatentExpiresType
8071073June 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.